MedPath

Efficacy of Clostridium butyricum M588 probiotics for the patients of constipation in schizophrenia: 4 weeks, a randomized, double blinded trial

Not Applicable
Recruiting
Conditions
Schizophrenia
Registration Number
JPRN-UMIN000025409
Lead Sponsor
Fujita Health University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1.Comatose patient 2.Patients under the strong influence of central nervous system depressants such as barbiturates, anesthetics 3.Patients under the influence of epinephrine 4.Patients under the influence of neurostimulatory substances such as stimulants and alcohol 5.Patients with a history of hypersensitivity to the ingredients of this drug 6.Patients who may be pregnant and pregnant 7.Patients with mental retardation 8.Patients with dementia combined 9.Patients with personality disorder complications 10.Patients diagnosed with irritable bowel syndrome by ROME III 11.Patients complicated of digestive organ diseases other than constipation 12.Patients already using live bacteria such as lactic acid bacteria and butyric acid bacteria

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath